Skip to content
Research/Exosome Therapies/IV Exosome Therapy

IV Exosome Therapy

Systemic exosome therapy for regenerative and longevity support. Therapy administered via IV.

Intelligence Profile

Research Papers

Key Research Papers and Clinical Trials

The available evidence for IV exosome therapy comes primarily from preclinical animal studies, with limited human clinical trial data.

Preclinical Research

Several animal studies have explored exosome therapy for neurological conditions. A 2026 study (PMID: 42046108) investigated exosomes derived from human umbilical cord mesenchymal stem cells in rats with intracerebral hemorrhage, finding that the therapy appeared to reduce neuroinflammation through modulation of lactylation modification. Another rat study (PMID: 41870687) examined bone marrow mesenchymal stem cell-derived exosomes for secondary brain injury after intracerebral hemorrhage, reporting effects on the SIRT6/Notch1/NF-κB signaling pathway.

Cardiovascular applications have also been studied, with research (PMID: 42047346) identifying miR-150-5p in human amniotic membrane mesenchymal cell-derived extracellular vesicles as potentially driving cardioprotection effects.

Additional preclinical work has focused on regenerative medicine applications, including a 2026 rat study (PMID: 41888589) examining endometrial regeneration using mesenchymal stem cells and exosomes for treating intrauterine adhesions.

Clinical Trial Evidence

The clinical trial landscape for IV exosome therapy remains limited. Current registered studies include:

  • A Phase 1 trial for lower back pain (NCT07587047) that is actively recruiting patients
  • A suspended study examining exosomes in craniofacial neuralgia (NCT04202783)
  • Several completed or terminated trials focused on exosome biomarkers rather than therapeutic applications

Evidence Limitations

The research base is heavily weighted toward animal studies, with minimal data from controlled human trials. Most clinical studies have focused on using exosomes as biomarkers rather than as therapeutic agents delivered intravenously. The translation from promising preclinical findings to proven clinical efficacy remains to be established through rigorous human trials.

This information is for research purposes only and should not be considered medical advice. Consult healthcare professionals for treatment decisions.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.